{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:43:50Z","timestamp":1786977830747,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3622,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Bone loss is a well-recognized complication of primary biliary cirrhosis (PBC). Although it has been suggested that alendronate might improve bone mineral density (BMD) in PBC, no randomized placebo-controlled trial has been conducted. The primary aim of this study was to compare the effects of alendronate versus placebo on BMD and biochemical measurements of bone turnover in patients with PBC-associated bone loss. We conducted a double-blinded, randomized, placebo-controlled trial. Patients with a PBC and BMD<\/jats:bold>\n                      <jats:bold>t<\/jats:bold>\n                      <jats:bold>score of less than \u22121.5 were randomized to receive 70 mg per week of alendronate or placebo over 1 year. BMD of the lumbar spine and proximal femur were measured at entry and at 1 year. Changes from baseline in BMD and biochemical measurements of bone turnover were assessed. Thirty-four patients were enrolled. Seventeen patients were randomized to each arm. After 1 year, a significantly larger improvement (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= .005) in spine BMD was observed in the alendronate group (0.09 \u00b1 0.03 g\/cm2 SD from baseline) compared with the placebo group (\u22120.003 \u00b1 0.02 g\/cm2 SD from baseline). A larger improvement (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= .046) was also observed in the femoral BMD of alendronate patients versus placebo. BMD changes were independent of concomitant estrogen therapy. The rate of adverse effects was similar in both groups.<\/jats:bold>\n                      <jats:underline>In conclusion<\/jats:underline>\n                      <jats:bold>, in patients with PBC-related bone loss, alendronate significantly improves BMD compared with placebo. Although in this study oral alendronate appears to be well tolerated in patients with PBC, larger studies are needed to formally evaluate safety. (Hepatology 2005;42:762\u2013771.)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.20866","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T18:18:21Z","timestamp":1127240301000},"page":"762-771","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":121,"title":["Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis: A Randomized Placebo-Controlled Trial * #"],"prefix":"10.1097","volume":"42","author":[{"given":"Claudia O.","family":"Zein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta A.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris E.","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill C.","family":"Keach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20250207","first-page":"299312","article-title":"Bone disease in obstructive jaundice.","volume":"25","author":"Atkinson","year":"1956","journal-title":"Q J Med"},{"key":"R3-6-20250207","doi-asserted-by":"crossref","first-page":"296300","DOI":"10.1002\/hep.1840140215","article-title":"Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis.","volume":"14","author":"Eastell","year":"1991","journal-title":"Hepatology"},{"key":"R4-6-20250207","first-page":"389392","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?","volume":"21","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"key":"R5-6-20250207","doi-asserted-by":"crossref","first-page":"316323","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.","volume":"35","author":"Menon","year":"2001","journal-title":"J Hepatol"},{"key":"R6-6-20250207","doi-asserted-by":"crossref","first-page":"855860","DOI":"10.7326\/0003-4819-103-6-855","article-title":"Bone loss and reduced osteoblast function in primary biliary cirrhosis.","volume":"103","author":"Hodgson","year":"1985","journal-title":"Ann Intern Med"},{"key":"R7-6-20250207","doi-asserted-by":"crossref","first-page":"323328","DOI":"10.1097\/00042737-199903000-00018","article-title":"Noninvasive assessment of bone density in primary biliary cirrhosis.","volume":"11","author":"Pereira","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R8-6-20250207","doi-asserted-by":"crossref","first-page":"295300","DOI":"10.1007\/s002239900622","article-title":"Bone density, vitamin D status, and disordered bone remodeling in endstage chronic liver disease.","volume":"64","author":"Crosbie","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"R9-6-20250207","doi-asserted-by":"crossref","first-page":"12841290","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"R10-6-20250207","doi-asserted-by":"crossref","first-page":"97102","DOI":"10.1016\/S0016-5085(82)80291-6","article-title":"Osteoporosis in primary biliary cirrhosis: effects of 25hydroxyvitamin D3 treatment.","volume":"83","author":"Matloff","year":"1982","journal-title":"Gastroenterology"},{"key":"R11-6-20250207","doi-asserted-by":"crossref","first-page":"217223","DOI":"10.1016\/0168-8278(91)90941-4","article-title":"Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study of calcitonin treatment.","volume":"12","author":"Floreani","year":"1991","journal-title":"J Hepatol"},{"key":"R12-6-20250207","doi-asserted-by":"crossref","first-page":"219224","DOI":"10.1016\/S0016-5085(97)70098-2","article-title":"Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after two years.","volume":"113","author":"Guanabens","year":"1997","journal-title":"Gastroenterology"},{"key":"R13-6-20250207","doi-asserted-by":"crossref","first-page":"878882","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis for primary biliary cirrhosis: a randomized trial.","volume":"33","author":"Lindor","year":"2000","journal-title":"J Hepatol"},{"key":"R14-6-20250207","doi-asserted-by":"crossref","first-page":"241245","DOI":"10.1007\/s005350050250","article-title":"Calcitriol for bone loss in patients with primary biliary cirrhosis.","volume":"34","author":"Shiomi","year":"1999","journal-title":"J Gastroenterol"},{"key":"R15-6-20250207","doi-asserted-by":"crossref","first-page":"54345","DOI":"10.1016\/S0168-8278(01)00133-7","article-title":"Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis.","volume":"35","author":"Nishiguchi","year":"2001","journal-title":"J Hepatol"},{"key":"R16-6-20250207","doi-asserted-by":"crossref","first-page":"889892","DOI":"10.1111\/j.1572-0241.2003.07341.x","article-title":"Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis.","volume":"98","author":"Menon","year":"2003","journal-title":"Am J Gastroenterology"},{"key":"R17-6-20250207","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1001\/jama.288.1.49","article-title":"Heart and Estrogenprogestin Replacement Study Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: The Heart and Estrogenprogestin Replacement Study FollowUp (HERS II).","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"R18-6-20250207","first-page":"321333","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial.","volume":"288","author":"Rossow","year":"2002","journal-title":"JAMA"},{"key":"R19-6-20250207","first-page":"17011712","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womens Health Initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R20-6-20250207","doi-asserted-by":"crossref","first-page":"404409","DOI":"10.1002\/lt.500040508","article-title":"Intravenous biphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.","volume":"4","author":"Reeves","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"R21-6-20250207","doi-asserted-by":"crossref","first-page":"11891199","DOI":"10.1056\/NEJMoa030897","article-title":"Alendronate Phase III Osteoporosis Treatment Study Group. Ten years experience with alendronate for osteoporosis in postmenopausal women.","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"R22-6-20250207","doi-asserted-by":"crossref","first-page":"22682274","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.","volume":"98","author":"Guanabens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R23-6-20250207","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making.","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"R24-6-20250207","first-page":"112","article-title":"Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate OnceWeekly Study Group.","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging"},{"key":"R25-6-20250207","first-page":"19881996","article-title":"Twoyear results of a onceweekly administration for the treatment of postmenopausal osteoporosis.","volume":"17","year":"2002","journal-title":"J Bone Miner Res"},{"key":"R26-6-20250207","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"R27-6-20250207","doi-asserted-by":"crossref","first-page":"793800","DOI":"10.7326\/0003-4819-128-10-199805150-00001","article-title":"The association of radiographically detected vertebral fractures with back pain and function: a prospective study.","volume":"128","author":"Nevitt","year":"1998","journal-title":"Ann Intern Med"},{"key":"R28-6-20250207","doi-asserted-by":"crossref","first-page":"16141621","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study.","volume":"14","author":"Garnero","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R30-6-20250207","first-page":"237244","article-title":"Ravn, P, Clemmesen B, Christiansen C Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.","volume":"24","year":"1999","journal-title":"Bone"},{"key":"R31-6-20250207","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1016\/S8756-3282(98)00144-6","article-title":"Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.","volume":"24","author":"Watts","year":"1999","journal-title":"Bone"},{"key":"R32-6-20250207","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.7326\/0003-4819-138-2-200301210-00007","article-title":"Heart and Estrogenprogestin Replacement Study Research Group. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogenprogestin Replacement Study.","volume":"138","author":"Vittinghoff","year":"2003","journal-title":"Ann Intern Med"},{"key":"R33-6-20250207","doi-asserted-by":"crossref","first-page":"383394","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with onceweekly alendronate and daily risedronate: a randomized, placebocontrolled study.","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"R34-6-20250207","doi-asserted-by":"crossref","first-page":"461468","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebocontrolled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass. Results of the FOSIT study.","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"R35-6-20250207","doi-asserted-by":"crossref","first-page":"11591164","DOI":"10.1001\/jama.1997.03540380073035","article-title":"Prevention of nonvertebral fractures by alendronate. A metaanalysis.","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA"},{"key":"R36-6-20250207","doi-asserted-by":"crossref","first-page":"281289","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"R37-6-20250207","doi-asserted-by":"crossref","first-page":"231236","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents is related to changes in bone density.","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-6-20250207","doi-asserted-by":"crossref","first-page":"15861592","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-6-20250207","doi-asserted-by":"crossref","first-page":"731738","DOI":"10.1359\/jbmr.1998.13.4.731","article-title":"Collagenrelated markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.","volume":"13","author":"Guanabens","year":"1998","journal-title":"J Bone Miner Res"},{"key":"R40-6-20250207","first-page":"8081","article-title":"Hormone replacement therapy in postmenopausal women: urinary Ntelopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.","volume":"105","author":"Chesnut","year":"1997","journal-title":"Am J Med"},{"key":"R41-6-20250207","first-page":"10161021","article-title":"Esophagitis associated with the use of alendronate.","volume":"335","author":"DeGroen","year":"1996","journal-title":"N Engl J Med"},{"key":"R42-6-20250207","doi-asserted-by":"crossref","first-page":"525528","DOI":"10.1016\/S0016-5107(98)70256-1","article-title":"Alendronateassociated esophagitis: endoscopic and pathologic features.","volume":"47","author":"Ribeiro","year":"1998","journal-title":"Gastrointest Endosc"},{"key":"R43-6-20250207","first-page":"11611162","article-title":"United Kingdom experience with alendronate and oesophageal reactions.","volume":"48","author":"Mackay","year":"1998","journal-title":"Br J Gen Pract"},{"key":"R44-6-20250207","doi-asserted-by":"crossref","first-page":"14511457","DOI":"10.1046\/j.1365-2036.2000.00864.x","article-title":"A randomized controlled trial to assess alendronateassociated injury of the upper gastrointestinal tract.","volume":"14","author":"Marshall","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R45-6-20250207","doi-asserted-by":"crossref","first-page":"753757","DOI":"10.1111\/j.1572-0241.1998.219_a.x","article-title":"Effects of alendronate on gastric and duodenal mucosa.","volume":"93","author":"Lanza","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R46-6-20250207","doi-asserted-by":"crossref","first-page":"515519","DOI":"10.1046\/j.1365-2036.1999.00488.x","article-title":"Alendronate gastric ulcers.","volume":"13","author":"Graham","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R47-6-20250207","doi-asserted-by":"crossref","first-page":"31123117","DOI":"10.1111\/j.1572-0241.2000.03258.x","article-title":"An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.","volume":"95","author":"Lanza","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R48-6-20250207","doi-asserted-by":"crossref","first-page":"517525","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate.","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"key":"R49-6-20250207","first-page":"365366","article-title":"Liver damage due to alendronate.","volume":"343","author":"Halabe","year":"2000","journal-title":"N Engl J Med"},{"key":"R50-6-20250207","first-page":"271272","article-title":"Hepatitis after alendronate.","volume":"53","author":"Lieverse","year":"1998","journal-title":"Neth J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20866","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200510000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:16:21Z","timestamp":1738926981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200510000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20866","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}